Pharmaceutical and consumer packaged goods company Johnson & Johnson (NYSE:JNJ) has been upgraded by Goldman Sachs to a neutral rating from a conviction sell rating. The firm also raised its price target on the stock to $112 from $102 a share.
The stock increased 0.50% or $0.54 on March 14, hitting $107.68. About 5,216 shares traded hands. Johnson & Johnson (NYSE:JNJ) has risen 8.72% since August 6, 2015 and is uptrending. It has outperformed by 11.67% the S&P500.
Source: Sonoran Weekly Review